tetano
Editor, Senior Moderator
Discov Med
. 2023 Apr 1;35(175):201-207.
doi: 10.24976/Discov.Med.202335175.21. Efficacy and Safety of Mesenchymal Stem Cells for COVID-19 Infection: A Meta-Analysis and Systematic Review
Li Chen[SUP] 1 [/SUP], Qinfei Xu[SUP] 2 [/SUP], Fen Sheng[SUP] 3 [/SUP], Beibei Wang[SUP] 4 5 [/SUP]
Affiliations
Background: COVID-19 (coronavirus disease 2019) is a pandemic around the world, and its treatment options often fail to achieve ideal results. There is a lot of controversy in the treatment of COVID-19 with mesenchymal stem cells (MSCs). The study aims to assess the safety and efficacy of mesenchymal treatment of new coronary pneumonia.
Methods: We manually searched electronic databases including PubMed, Embase, Cochrane Library, and Web of Science until 25th July 2022, and Stata 15.0 (StataCorpLLC: College Station, TX, USA) was used to analyze the data.
Results: A total of 8 randomized controlled trials were included, involving a total of 345 people, of which 180 were in the MSCs group and 165 were in the placebo group. The analysis results showed that MSCs can reduce mortality in COVID-19 patients compared to placebo [RR (Risk Ratio) = 0.56, 95% CI (Confidence Interval) (0.36, 0.89); p = 0.003]. There was no significant difference between the mesenchymal stem cell group and the placebo group in the incidence of adverse reactions [RR = 0.64, 95% CI (0.34, 1.18); p = 0.281]; In the SpO[SUB]2[/SUB]/FiO[SUB]2[/SUB] (Oxygen Saturation/Fraction of Inspiration O[SUB]2[/SUB]) [WMD (Weighted Mean Difference) = 9.07, 95% CI (-38.01, 56.15); p = 0.080]; In ICU (Intensive Care Unit) stay [WMD = -1.66, 95% CI (-7.23, 3.91); p = 0.131].
Conclusions: Mesenchymal stem cells can reduce the mortality of COVID-19 patients.
Keywords: COVID-19; adverse events; mesenchymal stem cells; systematic review.
. 2023 Apr 1;35(175):201-207.
doi: 10.24976/Discov.Med.202335175.21. Efficacy and Safety of Mesenchymal Stem Cells for COVID-19 Infection: A Meta-Analysis and Systematic Review
Li Chen[SUP] 1 [/SUP], Qinfei Xu[SUP] 2 [/SUP], Fen Sheng[SUP] 3 [/SUP], Beibei Wang[SUP] 4 5 [/SUP]
Affiliations
- PMID: 37105930
- DOI: 10.24976/Discov.Med.202335175.21
Background: COVID-19 (coronavirus disease 2019) is a pandemic around the world, and its treatment options often fail to achieve ideal results. There is a lot of controversy in the treatment of COVID-19 with mesenchymal stem cells (MSCs). The study aims to assess the safety and efficacy of mesenchymal treatment of new coronary pneumonia.
Methods: We manually searched electronic databases including PubMed, Embase, Cochrane Library, and Web of Science until 25th July 2022, and Stata 15.0 (StataCorpLLC: College Station, TX, USA) was used to analyze the data.
Results: A total of 8 randomized controlled trials were included, involving a total of 345 people, of which 180 were in the MSCs group and 165 were in the placebo group. The analysis results showed that MSCs can reduce mortality in COVID-19 patients compared to placebo [RR (Risk Ratio) = 0.56, 95% CI (Confidence Interval) (0.36, 0.89); p = 0.003]. There was no significant difference between the mesenchymal stem cell group and the placebo group in the incidence of adverse reactions [RR = 0.64, 95% CI (0.34, 1.18); p = 0.281]; In the SpO[SUB]2[/SUB]/FiO[SUB]2[/SUB] (Oxygen Saturation/Fraction of Inspiration O[SUB]2[/SUB]) [WMD (Weighted Mean Difference) = 9.07, 95% CI (-38.01, 56.15); p = 0.080]; In ICU (Intensive Care Unit) stay [WMD = -1.66, 95% CI (-7.23, 3.91); p = 0.131].
Conclusions: Mesenchymal stem cells can reduce the mortality of COVID-19 patients.
Keywords: COVID-19; adverse events; mesenchymal stem cells; systematic review.